抑郁症药物增强中的人工智能 (AID-ME):为个性化抑郁症治疗选择和管理提供深度学习支持的临床决策支持系统的集群随机试验
David Benrimoh1,2,3,4, Kate Whitmore1, Maud Richard1
1Aifred Health Inc, Montreal, Quebec, Canada.
The Journal of clinical psychiatry
|August 28, 2025
概括
人工智能 (AI) 临床决策支持系统 (CDSS) 在改善重大抑郁症 (MDD) 治疗结果方面表现有前途. 这项研究发现,与标准治疗相比,AI-CDSS显著增加了缓解率.
科学领域:
- 精神病学与心理健康
- 医疗信息学
- 临床决策支持
背景情况:
- 大型抑郁症的治疗选择缺乏个性化.
- 人工智能支持的临床决策支持系统 (CDSS) 正在为MDD管理而出现.
- 对AI-CDSS的临床验证是有限的.
研究的目的:
- 评估AI-CDSS在改善中度至重度MDD患者治疗结果方面的有效性.
- 评估预测抗抑郁药物缓解概率的AI-CDSS是否可以提高MDD的管理.
主要方法:
- 一个多中心,集群随机,盲目的试验,将AI-CDSS与MDD的门诊成年患者的标准护理进行比较.
- 患者通过门户网站填写问卷;活跃组的临床医生使用AI-CDSS.
- 主要结局是缓解,定义为蒙哥马利- 阿斯伯格抑郁评分表 (MADRS) 分数<11.
主要成果:
- 与对照组 (0%) 相比,AI-CDSS组的缓解率明显较高 (28.6%).
- 使用AI-CDSS的患者的改善速度更快.
- 没有严重的不良事件归因于AI-CDSS.
结论:
- 初步证据表明AI-CDSS可以改善中度至重度MDD的结果.
- 包括初级保健机构在内的更大样本的进一步研究是有必要的.
- 纵向使用AI-CDSS显示了个性化MDD治疗的潜力.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
340
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
340
Depression: Overview
331
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
331
Antidepressant Drugs: Overview
741
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
741
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Long-term Depression
31.4K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
31.4K
Drug Therapy
96
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
96


